LMO

Table. 3.

Parameters of delta checks in participant laboratories

Test Number of labs performing delta check (%) Time interval (month) Delta check method
DPC DD RD RPC RCV Random
AFP (N = 84) 30 (35.7%) 1 3 (10.0) 1 (3.3)
3 5 (16.7) 1 (3.3)
6 4 (13.3) 1 (3.3)
12 2 (6.5)
no limit 10 (33.3) 1 (3.3) 1 (3.3) 1 (3.3)
Total 24 (80.0) 2 (6.7) 1 (3.3) 1 (3.3) 3 (10.0)
CA125 (N = 79) 27 (34.2%) 1 2 (7.4)
3 5 (18.5) 1 (3.7)
6 4 (14.8) 1 (3.7)
12 2 (7.4)
no limit 12 (44.4)
Total 25 (92.6) 1 (3.7) 1 (3.7)
CA19-9 (N = 82) 28 (34.1%) 1 2 (6.9)
3 3 (10.3) 1 (3.4)
6 4 (13.8) 1 (3.4)
12 2 (6.9)
no limit 13 (44.8) 1 (3.4) 1 (3.4)
Total 24 (82.8) 1 (3.4) 1 (3.4) 1 (3.4) 1 (3.4)
CEA (N = 84) 30 (35.7%) 1 3 (10.0)
3 4 (13.3) 1 (3.3)
6 4 (13.3) 1 (3.3) 1 (3.3)
12 2 (6.7)
no limit 11 (36.7) 1 (3.3) 1 (3.3) 1 (3.3)
Total 24 (80.0) 3 (10.0) 1 (3.3) 1 (3.3) 1 (3.3)
PSA (N = 85) 33 (38.8%) 1 3 (9.1) 1
3 5 (15.2) 2 (6.1)
6 4 (12.1) 1 (3.0) 1 (3.0)
12 1 (3.0)
no limit 11 (33.3) 2 (6.1) 1 (3.0) 1 (3.0)
Total 24 (72.7) 5 (15.2) 1 (3.0) 1 (3.0) 3 (9.1)
TSH (N = 86) 32 (37.2%) 1 2 (6.3) 3 (9.4) 1 (3.1)
3 2 (6.3) 2 (6.3) 3 (9.4)
6 3 (9.4) 1 (3.1)
12 1 (3.1)
no limit 13 (40.6) 1 (3.1)
Total 21 (65.6) 5 (15.6) 3 (9.4) 1 (3.1) 2 (6.3)
T3 (N = 86) 32 (37.2%) 1 2 (6.3) 1 (3.1)
3 2 (6.3) 2 (6.3) 3 (9.4)
6 3 (9.4) 2 (6.3) 1 (3.1)
12 2 (6.3)
no limit 13 (40.6) 1 (3.1)
Total 22 (68.8) 4 (12.5) 3 (9.4) 1 (3.1) 2 (6.3)
free T4 (N = 86) 32 (37.2%) 1 2 (6.3) 1 (3.1)
3 2 (6.3) 2 (6.3) 3 (9.4)
6 3 (9.4) 2 (6.3) 1 (3.1)
12 2 (6.3)
no limit 13 (40.6) 1 (3.1)
Total 22 (68.8) 4 (12.5) 3 (9.4) 1 (3.1) 2 (6.3)

Abbreviations: AFP, alpha-fetoprotein; CA125, cancer antigen 125; CA19-9, cancer antigen 19-9; CEA, carcinoembryonic antigen; DD, delta difference; DPC, delta percent change; Labs, laboratories; PSA, prostate-specific antigen; RCV, reference change value; RPC, rate percent change; TSH, thyroid-stimulating hormone; T3, triiodothyronine; T4, thyroxine.

Lab Med Online 2023;13:324~331 https://doi.org/10.47429/lmo.2023.13.4.324
© Lab Med Online